RAPT Therapeutics Ownership
| RAPT Stock | USD 1.20 0.01 0.84% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 39 M | Current Value 39 M | Avarage Shares Outstanding 25.3 M | Quarterly Volatility 13.6 M |
RAPT |
RAPT Stock Ownership Analysis
About 96.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.66. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. RAPT Therapeutics recorded a loss per share of 2.78. The entity had not issued any dividends in recent years. The firm had 21:1 split on the December 14, 2010. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 88 people. To find out more about RAPT Therapeutics contact Brian MD at 650 489 9000 or learn more at https://www.rapt.com.Besides selling stocks to institutional investors, RAPT Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different RAPT Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align RAPT Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
RAPT Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of RAPT Therapeutics are currently held by insiders. Unlike RAPT Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against RAPT Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of RAPT Therapeutics' insider trades
RAPT Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as RAPT Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading RAPT Therapeutics backward and forwards among themselves. RAPT Therapeutics' institutional investor refers to the entity that pools money to purchase RAPT Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Euclidean Capital Llc | 2024-09-30 | 657.9 K | Alphabet Inc | 2024-09-30 | 540.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 525.2 K | Two Sigma Investments Llc | 2024-09-30 | 520.4 K | Pale Fire Capital Se | 2024-09-30 | 510.7 K | Redmile Group, Llc | 2024-09-30 | 504.5 K | Cormorant Asset Management, Llc | 2024-09-30 | 496.8 K | Goldman Sachs Group Inc | 2024-09-30 | 397.8 K | Sio Capital Management, Llc | 2024-09-30 | 315 K | Fmr Inc | 2024-09-30 | 5.2 M | Vanguard Group Inc | 2024-09-30 | 3.2 M |
RAPT Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RAPT Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on RAPT Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RAPT Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RAPT Therapeutics Outstanding Bonds
RAPT Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. RAPT Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RAPT bonds can be classified according to their maturity, which is the date when RAPT Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.